The invention comprises compounds of the general formula <FORM:1017613/C2/1> and their pharmaceutically acceptable acid addition salts, wherein R1 is a C1-4 alkyl radical; R2 is a hydrogen or halogen atom, a C1-4 alkyl or alkoxy group; R3 is a hydrogen or halogen atom, a hydroxyl radical, a C1-4 alkyl, alkoxy, alkanoyloxy, or alkanoylamino radical or an amino group; R4 is a hydrogen atom or a C1-4 alkyl group and X is a straight saturated or mono-unsaturated trivalent aliphatic hydrocar bon radical having 3 to 5 carbon atoms, the two exterior valencies of which are bound to the benzene nucleus and which may be substituted by an oxo radical, a hydroxyl group, a C1-4 alkoxy or alkanoyloxy radical, a chlorine atom or by at most two C1-4 alkyl radicals, and the preparation thereof by (a) reacting a compound of the formula <FORM:1017613/C2/2> with a reactive ester of a compound of the formula <FORM:1017613/C2/3> or (b) reacting a compound of Formula (II) with a compound of the formula <FORM:1017613/C2/4> to give a compound of the formula <FORM:1017613/C2/5> wherein R5 is a hydrogen atom or a C1-4 alkyl radical, Y and Z are alkylidene or alkylene radicals which complete the 1-hydroxy-ethanyl-2-ylidene radical or the 1-hydroxy-1-alkyl-1-ethanyl-2-ylidene radical in Formula (V) to a hydroxy-substituted radical according to the definition of X, and wherein one of the two symbols may represent a direct linkage, or (c) by reacting a compound of Formula (II) with a compound of the formula <FORM:1017613/C2/6> to give a compound of the formula <FORM:1017613/C2/7> wherein Y1 and Z1 are alkylidene or alkylene radicals which complete the 1-ethenyl-2-ylidene or the 1-alkyl-1-ethenyl-2-ylidene radical of Formula (VII), to form radicals which correspond to X, and wherein one of the two symbols may also represent a direct linkage and, wherein R5 is a hydrogen atom, reacting this with a reactive methanol ester and reducing or hydrolysing the semi-cyclical imine double bond of the resulting methyl substituted immonium salt, or, if desired, directly reducing or hydrolysing the enamine double bond of the reaction product of Formula (VII), or (d) etherifying or acylating compounds containing as R3 or as a substituent in X an hydroxyl group or hydrolysing corresponding alkanoyl oxy groups, or (e) reducing or hydrogenating a reaction product having an oxo radical in X, to a compound having a hydroxyl group in X, or oxidizing a reaction product having a hydroxyl group in X to a compound having an oxo group in X, or (f) reacting a product having a hydroxyl group in the radical X with a sulphonic acid chloride, an inorganic acid chloride, phosgene or oxalyl chloride to form a compound of Formula (I) having a chlorine atom in the corresponding position, or (g) dehydrohalogenating a compound formed in (f) or dehydrating a compound having in X an hydroxyl group to give a compound of Formula I having a double bond in X, or (h) hydrogenating or reducing compounds having a double bond in X, or (2) acylating a compound having R3 as an amino group to an acylamino group or hydrolysing a compound having R3 as an acylamino group to an amino group.  7 - Bromo - 6,7,8,9 - tetrahydro - 5H - benzocycloheptene is prepared by reducing 6,7,8,9-tetrahydro - 5H - benzocycloheptene - 7 - one to the corresponding 7-ol and brominating this.  7 - (p - Toluenesulphonyloxy) - 6,7,8,9 - tetrahydro - 5H - benzocycloheptene is prepared from the 7-ol and tosyl chloride.  5 - Methyl - 2,3 - epoxytetralin is obtained from 1,4 - dihydro - 5 - methyl - naphthalene and perbenzoic acid.  1:4 - Diethyl - 2,3 - epoxytetralin is also prepared.  Pharmaceutical compositions comprise the compounds of Formula I together with a pharmaceutically acceptable carrier in forms suitable for parenteral or oral administration.  The compositions have analgetic, antitussive, and spasmolytic activity.